Device Trial Radar · NCT07764055
A Trial of Absorbable Regenerated Oxidized Cellulose for Surgical Hemostasis)
Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
288
Actual
Start
Nov 9, 2022
Primary completion
Jan 15, 2024
Study completion Mar 5, 2024
Sponsor
- Lead sponsor
- Medprin Regenerative Medical Technologies Co., Ltd.Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Sir Run Run Shaw Hospital; Tongji Hospital, Tongji Medical College, HUST; Zhejiang Provincial People's Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; The First Affiliated Hospital of Guangzhou Medical University
- First posted
- Aug 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, single-blind, positive-controlled, non-inferiority clinical trial. The purpose is to evaluate the safety and effectiveness of the absorbable multilayer fibrillar regenerated oxidized cellulose in controlling capillary, venous, and small arteriole bleeding during surgical procedures when ligation or other conventional methods are ineffective or impractical. A total of 288 subjects (144 in the test group, 144 in the control group) will be enrolled across 6 centers (General Surgery, Cardiothoracic Surgery, Gynecology, and Urology). Subjects will be followed up at 30±15 days and 180±30 days post-surgery. The primary efficacy endpoint is the hemostasis success rate within 5 minutes.
Conditions
- Surgical Bleeding
- Hemorrhage
- Oxidized Regenerated Cellulose
Interventions
Absorbable Multilayer Fibrillar Regenerated Oxidized CelluloseDevice
A sterile, absorbable, multilayer fibrillar regenerated oxidized cellulose dressing intended for use as an adjunctive hemostatic agent to control capillary, venous, and small arteriole bleeding during surgical procedures. The product is applied directly to the bleeding site and can be layered as needed. It is absorbed in the body over time.
SURGICEL Absorbable Hemostat (Absorbable Hemostatic Gauze)Device
A sterile, absorbable oxidized regenerated cellulose hemostatic dressing indicated for use as an adjunctive hemostatic agent to control capillary, venous, and small arteriole bleeding during surgical procedures. The product is applied directly to the bleeding site and is absorbed in the body.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hemostasis Success Rate within 5 MinutesTime frame: Intraoperative (Day of surgery)
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Hangzhou, China
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.